Study summary · 2022 · Evidence review

COPD home monitoring: uncertain clinical benefit

COPD monitoring did not consistently improve quality of life or utilization; low-certainty evidence leaves important uncertainty.

Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence

Original publication

Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review

Fernanda Inagaki Nagase; Tania Stafinski; Melita Avdagovska; Michael K. Stickland; Evelyn Melita Etruw; Devidas Menon

University of Alberta; Alberta Health Services; Covenant Health, Canada

BMC Health Services Research · Online: · Issue: 2022

Journal version of record. · Full text consulted.

What was studied

Design
Evidence review
Population
People with COPD
Sample
19 studies: 17 randomized trials and 2 comparative observational studies; 3,144 participants
Intervention
Home transmission of symptoms and measurements, with differing feedback pathways
Comparator
Usual care or monitoring without provider feedback
Follow-up
Monitoring periods of 1–12 months
Study/data period
Included studies conducted in 2006–2018
Review search cutoff
2020-03-13
Setting
Multiple countries

Methods

Narrative review with limited pooling, risk-of-bias assessment and GRADE. Designs and monitoring technologies differed.

Findings

Quality of life showed no clear between-group improvement. Seven of nine dedicated-device studies reported similar COPD hospitalization results; two favored monitoring. One study assessed adverse events and eight assessed mortality, without clear group differences.

Limitations

Evidence certainty was low or very low. Short follow-up, heterogeneous interventions and incomplete reporting limit inference. Sparse safety data do not establish safety equivalence.

What this means for care delivery

Do not transfer heart-failure or hypertension benefits to COPD. Provider feedback is promising, but its independent effect is not established across programs.